Momenta Pharmaceuticals, Inc.
675 West Kendall Street
About Momenta Pharmaceuticals, Inc.
Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. We are applying our innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of complex generics, biosimilars and novel drugs designed to address a variety of medical needs.
In April 2015, Momenta announced the FDA approval of once daily Glatopa™ (glatiramer acetate injection), a fully substitutable generic version of Copaxone® 20 mg/mL. Glatopa was developed under a collaboration agreement between Momenta and Sandoz and is the second complex generic developed by Momenta to receive FDA approval.
In July 2010, Momenta announced the FDA approval of our first drug, Enoxaparin Sodium Injection developed in collaboration with Sandoz.
327 articles with Momenta Pharmaceuticals, Inc.
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
10/8/2018Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.
Momenta Pharmaceuticals, Inc. today announced that it will host a live webcast of its R&D Day on Thursday, October 11, 2018 beginning at 8:30 am ET. The event is being held in New York, NY.
Despite winning regulatory approval for a copycat version of Copaxone earlier this year, Cambridge, Mass.-based Momenta Pharmaceuticals has completed a strategic review that includes slashing its staff by 50 percent as the company focuses its resources on two biosimilar candidates in its pipeline.
Here’s a look at eight biopharma companies with upcoming catalysts.
Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Mallinckrodt, Momenta Pharma, Mylan, and Neurocrine Biosciences
WallStEquities.com is offering reports on MNK, MNTA, MYL, and NBIX which can be accessed for free by signing up to www.wallstequities.com/registration.
2/23/2018Teva Pharmaceuticals will close its offices in Washington, D.C. and New York City as part of the cost-cutting measures.
Teva and Mylan are looking over their shoulders this morning after the FDA gave Novartis and Momenta the green light for their Copaxone copycat drug.
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast
Management will host a conference call on that date at 10:00 a.m. EST to discuss these results and provide an update on the company.
Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa (Glatiramer Acetate Inj...
1/30/2018The FDA has classified the outcome of its fourth quarter 2017 reinspection of Pfizer’s McPherson facility as Voluntary Action Indicated.
Momenta Pharmaceuticals Reports Positive Top-Line Phase I Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers
M281 data shows safety and tolerability with no serious adverse events.
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept)
The companies plan to initiate a pivotal clinical trial in patients in the first half of 2018.
In Q3 of 2017, the Company recorded $10.9 million in product revenues from Sandoz’s sales of Glatopa 20 mg compared to $23.3 million for the same period in 2016.
Momenta Pharmaceuticals Announces Date of Third Quarter 2017 Financial Results Conference Call and Webcast
Management will host a conference call on that date at 10:00 a.m. EDT to discuss these results and provide an update on the company.